CAMBRIDGE, Mass.--(BUSINESS WIRE)--Gloucester Pharmaceuticals, Inc., an oncology focused specialty pharmaceutical company, today announced encouraging interim results from an investigator-sponsored phase I/II dose-escalation study investigating the use of the Company’s lead product, romidepsin, in combination with bortezomib (Velcade®) and dexamethasone to treat patients with relapsed/refractory multiple myeloma. These interim results were reported at the 49th Annual Meeting of the American Society of Hematology (ASH) being held in Atlanta, Georgia. Full text of the abstract #1167 can be viewed on the ASH website at www.hematology.org.
